Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

The Price to Operating Profit (P/OP) ratio for the analyzed period exhibits considerable fluctuation, generally increasing from 2013 before declining in recent years. Initial values are unavailable until 2013, at which point the ratio begins at 35.11. A general upward trend is then observed through 2015, peaking at 49.17, followed by a decline to 28.70 in 2017. Subsequent years show continued volatility, with a significant drop to 7.55 in 2022 before rising again to 22.90 in 2024.

Overall Trend

The P/OP ratio demonstrates a lack of consistent direction. While an increasing trend is apparent between 2013 and 2015, this is followed by periods of decline and fluctuation. The most recent values suggest a potential stabilization, but further observation is needed to confirm this.

Peak and Trough Values

The highest recorded P/OP ratio is 49.17 in 2015, indicating a period where the market valued each dollar of operating profit at approximately 49 dollars. Conversely, the lowest value of 7.55 in 2022 suggests a significantly lower valuation, potentially reflecting market concerns or a shift in investor sentiment.

Recent Performance (2020-2024)

From 2020 to 2024, the P/OP ratio has been particularly volatile. It decreased from 19.01 in 2020 to 14.82 in 2021, then experienced a substantial decline to 7.55 in 2022. A recovery is then seen in 2023 and 2024, reaching 18.01 and 22.90 respectively. This recent period suggests a dynamic relationship between share price and operating profit, potentially influenced by external factors or company-specific events.

The fluctuations in the P/OP ratio warrant further investigation to understand the underlying drivers. Changes in market conditions, investor expectations, and the company’s financial performance likely contribute to these observed patterns.